Mads Krogsgaard Thomsen/LinkedIn
Dec 16, 2025, 16:34
Mads Krogsgaard Thomsen on Novo Nordisk Haemophilia Foundation’s Support for Haemoglobinopathies
Mads Krogsgaard Thomsen, CEO at Novo Nordisk Foundation, shared on LinkedIn:
”Haemophilia and other blood disorders like sickle cell disease and thalasaemia are chronic, debilitating diseases.
As is often the case, global health inequity is very pronounced, with under-diagnosis, under-treament and poor outcomes as a result in many low and middle income countries.
It is therefore a pleasure to announce that Novo Nordisk Foundation is stepping up, both in absolute funding terms, and in adding the haemoglobinopathy disorders to our support to the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation in these areas.”
Read the full announcement here.
Stay updated with Hemostasis Today.
-
Jun 29, 2026, 20:09Mamta Soni: The Role of Anti-Xa Monitoring in Anticoagulation Management
-
Jun 29, 2026, 20:07Nita Radhakrishnan: Discussing Risks, Benefits, and Uncertainties in Hemoglobinopathy Care
-
Jun 29, 2026, 20:05Anisha Navkudkar: TMH Blood Centre Received the Ravi Reddy Award 2026 at ISBT Congress
-
Jun 29, 2026, 20:03Anirban Sen Gupta: Congratulations Christopher Delianides for a Fantastic Dissertation and Graduate Research Presentation
-
Jun 29, 2026, 20:01May Guo: Inhibiting Anti-PEG Antibody Binding With Randomized PEG
-
Jun 29, 2026, 15:50Sweta Agrawal: Expanding Care for PNH Patients in Nepal
-
Jun 29, 2026, 15:17Heghine Khachatryan: Hemostasis at the Crossroads of Thrombosis and Bleeding
-
Jun 29, 2026, 15:07Tomaz Crochemore: From Bleeding to Thrombosis – The Era of Precision Hemostatic Medicine Has Arrived
-
Jun 29, 2026, 14:51Pete Stibbs: Building a Successful Venous Thrombectomy Practice